| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 48.7 | 58.5 | 45.2 |
| Other income | 2.4 | 0.8 | 0.4 |
| Total income | 51.1 | 59.2 | 45.6 |
| Profit before exceptional items & tax | -5.8 | -5.1 | -6.1 |
| Profit before tax | -5.8 | -5.1 | -6.1 |
| Net profit | -5.7 | -5.0 | -5.6 |
| Operating margin | -11.4% | -8.6% | -13.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +7.70% |
|---|---|
| Operating profit, year on year | -26.20% |
| Operating profit, quarter on quarter | -39.00% |
NSE results filing, NSE: NATCAPSUQ. Figures extracted from the filing.
Natural Capsules Ltd: key numbers
- Share price
- ₹161.01
- Market cap
- ₹167.6 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -7.8×Sector 47.4×
- Promoter holding
- 50.92%-0.12% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Annual General Meeting
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Fund Raise of ₹10.01 Cr
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
- Value
- ₹10.01 Cr
Natural Capsules Board Meeting Date
Natural Capsules Limited is holding a board meeting at shorter notice on September 02, 2026, to revise the issue price and quantity for its proposed preferential issue.
Natural Capsules Annual General Meeting
Natural Capsules Limited has issued a notice for an EGM to approve a Rs. 10.00 Crore preferential allotment of equity shares and warrants to a promoter.
- Value
- ₹10.00 Cr
Natural Capsules Investor Presentation: Key Takeaways
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Results Update
Natural Capsules Limited announced its Q1FY27 financial results. The company highlighted operational performance, market demand, and new contract manufacturing agreements for its business segments.